文献速递精神分裂症与精神病性障碍

精神分裂症患者抗精神病药多药联用与单药治疗的安全性:全国队列研究

Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
PubMed 文献 · Am J Psychiatry · 2023-03-22

该研究基于芬兰全国住院登记数据,纳入61,889例精神分裂症患者,随访1996-2017年,采用个体内分析比较抗精神病药多药联用与单药治疗在七个剂量类别下严重躯体疾病住院风险。结果显示,在总剂量>1.1 DDDs/日时,多药联用者的非精神科住院风险显著低于单药治疗者;最高剂量类别下心血管住院风险也显著降低。结论提示单药治疗并不比多药联用更安全。

要点

  • 在总剂量>1.1 DDDs/日时,多药联用的非精神科住院风险显著低于单药治疗。
  • 最高剂量类别(≥1.6 DDDs/日)多药联用的心血管住院风险显著低于单药治疗。
  • 任何多药联用与任何单药治疗的总体比较无显著差异。

核心结论

  • 抗精神病药单药治疗与多药联用相比,并未降低严重躯体疾病住院风险。

研究设计与样本

  • 基于芬兰全国住院登记的前瞻性队列研究,纳入61,889例精神分裂症患者,中位随访14.8年(IQR=7.4-22.0),随访期1996-2017年。
  • 采用个体内分析比较多药联用与单药治疗在七个剂量类别(<0.4至≥1.6 DDDs/日)下的严重躯体疾病住院风险。

主要发现

  • 在总剂量>1.1 DDDs/日的所有类别中,多药联用者的非精神科住院风险显著低于单药治疗者,差异达-13%。
  • 1.1-<1.4 DDDs/日:调整后风险比=0.91,95% CI=0.87-0.95;1.4-<1.6 DDDs/日:调整后风险比=0.91,95% CI=0.86-0.96;≥1.6 DDDs/日:调整后风险比=0.87,95% CI=0.84-0.89。
  • 最高总剂量类别(≥1.6 DDDs/日)多药联用的心血管住院风险显著降低18%(调整后风险比=0.82,95% CI=0.72-0.94)。
  • 任何多药联用与任何单药治疗的比较,非精神科或心血管住院风险均无显著差异。

临床怎么用

  • 在缺乏安全性证据的情况下,治疗指南不应鼓励用单药治疗替代抗精神病药多药联用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The authors sought to study the safety of antipsychotic polypharmacy compared with monotherapy in specific dosage categories. METHODS: Patients with schizophrenia (N=61,889; median follow-up, 14.8 years [IQR=7.4-22.0]) were identified from the Finnish nationwide inpatient care register and followed up over the period 1996-2017. Antipsychotic polypharmacy was compared with monotherapy in seven dosage categories (<0.4, 0.4-<0.6, 0.6-<0.9, 0.9-<1.1, 1.1-<1.4, 1.4-<1.6, and ≥1.6 defined daily doses [DDDs] per day) in terms of risk of severe physical morbidity, indicated by nonpsychiatric and cardiovascular hospitalizations (adjusted hazard ratio). Within-individual analysis was used in an effort to eliminate selection bias. RESULTS: The mean age of the cohort was 46.7 years (SD=16.0), and 50.3% (N=31,104) were men. Among patients who had used both monotherapy and polypharmacy, the risk of nonpsychiatric hospitalization was significantly lower during polypharmacy use at all total dosage categories above 1.1 DDDs/day with differences up to -13% than during monotherapy use of the same dosage category (for 1.1-<1.4 DDDs/day, adjusted hazard ratio=0.91, 95% CI=0.87-0.95; for 1.4-<1.6 DDDs/day, adjusted hazard ratio=0.91, 95% CI=0.86-0.96; and for ≥1.6 DDDs/day, adjusted hazard ratio=0.87, 95% CI=0.84-0.89). The risk of cardiovascular hospitalization was significantly lower for polypharmacy at the highest total dosage category (-18%, adjusted hazard ratio=0.82, 95% CI=0.72-0.94). The results from the comparisons between monotherapy and no use and between polypharmacy and no use were in line with the primary comparison of polypharmacy and monotherapy within the same individual. Comparison of any polypharmacy use with any monotherapy use showed no significant difference for nonpsychiatric or cardiovascular hospitalization. CONCLUSIONS: The results show that antipsychotic monotherapy is not associated with a lower risk of hospitalization for severe physical health problems when compared with antipsychotic polypharmacy. Treatment guidelines should not encourage use of monotherapy instead of antipsychotic polypharmacy without any existing evidence on the safety issues.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Taipale H, Tanskanen A, Tiihonen J, et al. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia. Am J Psychiatry. 2023. PMID: 36945825. doi:10.1176/appi.ajp.20220446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。